Financhill
Sell
48

SUPN Quote, Financials, Valuation and Earnings

Last price:
$32.62
Seasonality move :
4.94%
Day range:
$32.28 - $32.85
52-week range:
$25.53 - $40.28
Dividend yield:
0%
P/E ratio:
29.37x
P/S ratio:
2.73x
P/B ratio:
1.77x
Volume:
355.6K
Avg. volume:
421.1K
1-year change:
18.5%
Market cap:
$1.8B
Revenue:
$661.8M
EPS (TTM):
$1.11

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SUPN
Supernus Pharmaceuticals
$147.9M $0.37 -8.33% 38.89% $38.80
COLL
Collegium Pharmaceutical
$173.1M $1.45 25.46% 251.92% $41.25
CORT
Corcept Therapeutics
$177.9M $0.14 21.73% -41.41% $138.25
LLY
Eli Lilly and
$12.7B $3.46 26.74% 68.13% $955.31
PFE
Pfizer
$14.1B $0.67 1.07% 5523.4% $29.50
ZTS
Zoetis
$2.2B $1.40 1.9% 17.3% $194.43
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SUPN
Supernus Pharmaceuticals
$32.60 $38.80 $1.8B 29.37x $0.00 0% 2.73x
COLL
Collegium Pharmaceutical
$29.48 $41.25 $947.6M 24.16x $0.00 0% 1.71x
CORT
Corcept Therapeutics
$76.81 $138.25 $8.1B 66.22x $0.00 0% 13.00x
LLY
Eli Lilly and
$725.22 $955.31 $651.1B 59.01x $1.50 0.77% 13.37x
PFE
Pfizer
$23.61 $29.50 $134.2B 17.11x $0.43 7.2% 2.16x
ZTS
Zoetis
$166.26 $194.43 $74B 29.85x $0.50 1.12% 8.10x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SUPN
Supernus Pharmaceuticals
-- 0.251 -- 2.16x
COLL
Collegium Pharmaceutical
78.13% -0.093 87.34% 0.88x
CORT
Corcept Therapeutics
-- -1.371 -- 2.69x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
PFE
Pfizer
40.42% 0.423 42.46% 0.88x
ZTS
Zoetis
58.56% 0.874 9.26% 0.91x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SUPN
Supernus Pharmaceuticals
$134.1M -$2.6M 6.24% 6.24% -1.73% $30.3M
COLL
Collegium Pharmaceutical
$97.3M $20.9M 4.51% 19.31% 13.45% $54.6M
CORT
Corcept Therapeutics
$154.8M $3.4M 21.3% 21.3% 2.17% $5M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B
ZTS
Zoetis
$1.6B $846M 21.88% 51.03% 38.92% $438M

Supernus Pharmaceuticals vs. Competitors

  • Which has Higher Returns SUPN or COLL?

    Collegium Pharmaceutical has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 1.36%. Supernus Pharmaceuticals's return on equity of 6.24% beat Collegium Pharmaceutical's return on equity of 19.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
    COLL
    Collegium Pharmaceutical
    54.75% $0.07 $1.1B
  • What do Analysts Say About SUPN or COLL?

    Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 19.02%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 39.93%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SUPN
    Supernus Pharmaceuticals
    2 3 0
    COLL
    Collegium Pharmaceutical
    2 1 0
  • Is SUPN or COLL More Risky?

    Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.082%.

  • Which is a Better Dividend Stock SUPN or COLL?

    Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SUPN or COLL?

    Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Supernus Pharmaceuticals's net income of -$11.8M is lower than Collegium Pharmaceutical's net income of $2.4M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.37x while Collegium Pharmaceutical's PE ratio is 24.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.73x versus 1.71x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SUPN
    Supernus Pharmaceuticals
    2.73x 29.37x $149.8M -$11.8M
    COLL
    Collegium Pharmaceutical
    1.71x 24.16x $177.8M $2.4M
  • Which has Higher Returns SUPN or CORT?

    Corcept Therapeutics has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 13.07%. Supernus Pharmaceuticals's return on equity of 6.24% beat Corcept Therapeutics's return on equity of 21.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
    CORT
    Corcept Therapeutics
    98.47% $0.17 $683.3M
  • What do Analysts Say About SUPN or CORT?

    Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 19.02%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 79.99%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SUPN
    Supernus Pharmaceuticals
    2 3 0
    CORT
    Corcept Therapeutics
    2 0 0
  • Is SUPN or CORT More Risky?

    Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

  • Which is a Better Dividend Stock SUPN or CORT?

    Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SUPN or CORT?

    Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Supernus Pharmaceuticals's net income of -$11.8M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.37x while Corcept Therapeutics's PE ratio is 66.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.73x versus 13.00x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SUPN
    Supernus Pharmaceuticals
    2.73x 29.37x $149.8M -$11.8M
    CORT
    Corcept Therapeutics
    13.00x 66.22x $157.2M $20.5M
  • Which has Higher Returns SUPN or LLY?

    Eli Lilly and has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.68%. Supernus Pharmaceuticals's return on equity of 6.24% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About SUPN or LLY?

    Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 19.02%. On the other hand Eli Lilly and has an analysts' consensus of $955.31 which suggests that it could grow by 31.73%. Given that Eli Lilly and has higher upside potential than Supernus Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Supernus Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SUPN
    Supernus Pharmaceuticals
    2 3 0
    LLY
    Eli Lilly and
    16 5 1
  • Is SUPN or LLY More Risky?

    Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock SUPN or LLY?

    Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.77% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SUPN or LLY?

    Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.37x while Eli Lilly and's PE ratio is 59.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.73x versus 13.37x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SUPN
    Supernus Pharmaceuticals
    2.73x 29.37x $149.8M -$11.8M
    LLY
    Eli Lilly and
    13.37x 59.01x $12.7B $2.8B
  • Which has Higher Returns SUPN or PFE?

    Pfizer has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.63%. Supernus Pharmaceuticals's return on equity of 6.24% beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About SUPN or PFE?

    Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 19.02%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 24.95%. Given that Pfizer has higher upside potential than Supernus Pharmaceuticals, analysts believe Pfizer is more attractive than Supernus Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SUPN
    Supernus Pharmaceuticals
    2 3 0
    PFE
    Pfizer
    7 15 1
  • Is SUPN or PFE More Risky?

    Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock SUPN or PFE?

    Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.2% to investors and pays a quarterly dividend of $0.43 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios SUPN or PFE?

    Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Pfizer's net income of $3B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.37x while Pfizer's PE ratio is 17.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.73x versus 2.16x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SUPN
    Supernus Pharmaceuticals
    2.73x 29.37x $149.8M -$11.8M
    PFE
    Pfizer
    2.16x 17.11x $13.7B $3B
  • Which has Higher Returns SUPN or ZTS?

    Zoetis has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 28.42%. Supernus Pharmaceuticals's return on equity of 6.24% beat Zoetis's return on equity of 51.03%.

    Company Gross Margin Earnings Per Share Invested Capital
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
    ZTS
    Zoetis
    71.98% $1.41 $11.2B
  • What do Analysts Say About SUPN or ZTS?

    Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 19.02%. On the other hand Zoetis has an analysts' consensus of $194.43 which suggests that it could grow by 16.95%. Given that Supernus Pharmaceuticals has higher upside potential than Zoetis, analysts believe Supernus Pharmaceuticals is more attractive than Zoetis.

    Company Buy Ratings Hold Ratings Sell Ratings
    SUPN
    Supernus Pharmaceuticals
    2 3 0
    ZTS
    Zoetis
    10 5 0
  • Is SUPN or ZTS More Risky?

    Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Zoetis has a beta of 0.942, suggesting its less volatile than the S&P 500 by 5.835%.

  • Which is a Better Dividend Stock SUPN or ZTS?

    Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.12% to investors and pays a quarterly dividend of $0.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SUPN or ZTS?

    Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Zoetis quarterly revenues of $2.2B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Zoetis's net income of $631M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.37x while Zoetis's PE ratio is 29.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.73x versus 8.10x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SUPN
    Supernus Pharmaceuticals
    2.73x 29.37x $149.8M -$11.8M
    ZTS
    Zoetis
    8.10x 29.85x $2.2B $631M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is down 11.95% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is down 1.76% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock